Intensive induction chemotherapy followed by myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for young children newly‐diagnosed with central nervous system atypical teratoid/rhabdoid tumors: The head start III experience
Wafik Zaky(The University of Texas MD Anderson Cancer Center), Jonathan L. Finlay(The Ohio State University), Kelley Haley(Children's Hospital of Los Angeles), Sharon L. Gardner(NYU Langone Health), Kamnesh R. Pradhan(Boston Children's Hospital), Richard Sposto(Children's Hospital of Los Angeles), Joseph C. Torkildson(UCSF Benioff Children's Hospital), Salvatore Bertolone(University of Louisville), Girish Dhall(Northwestern University), Mark Atlas(Long Island Jewish Medical Center), Jeffrey C. Allen(Eglin Air Force Base), Ramesh Patel(Miller Children's & Women's Hospital), Stephen J. Thompson(St. Jude Children's Research Hospital), Albert Cornelius(Spectrum Health), Violet Shen(Ruhr University Bochum), Lingyun Ji(University of Southern California)
Cited by 110
Related Papers
The genetic landscape of high-risk neuroblastoma
|Nature Genetics|2013|1.2k
The treatment of medulloblastoma
|Journal of neurosurgery|1990|583
Randomized Study of Two Chemotherapy Regimens for Treatment of Low-Grade Glioma in Young Children: A Report From the Children's Oncology Group
|Journal of Clinical Oncology|2012|433
Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis
|The Lancet Oncology|2013|404